European approval of intramuscular route of administration for peginterferon beta-1a (Plegridy)

The new intramuscular route of administration is intended for the existing formulation (125 micrograms in 0.5 ml) in the treatment of adult patients with relapsing remitting multiple sclerosis. Supporting data showed fewer injection site reactions vs subcutaneous administration.

Source:

PharmaTimes